Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 
The feature you requested does not exist. However, we suggest the following feature:

Global Canavan Disease Pipeline Review, H2 2016 Featuring Turing Pharmaceuticals AG - Research and Markets

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2016 | 04:38pm CET

Research and Markets has announced the addition of the "Canavan Disease - Pipeline Review, H2 2016" report to their offering.

The Pharmaceutical and Healthcare latest pipeline guide Canavan Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Canavan Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Canavan Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Canavan Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively. Canavan Disease.

Canavan Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Canavan Disease Overview
  3. Therapeutics Development
  4. Pipeline Products for Canavan Disease - Overview
  5. Pipeline Products for Canavan Disease - Comparative Analysis
  6. Canavan Disease - Therapeutics under Development by Companies
  7. Canavan Disease - Therapeutics under Investigation by Universities/Institutes
  8. Canavan Disease Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Canavan Disease - Products under Development by Companies
  13. Canavan Disease - Products under Investigation by Universities/Institutes
  14. Canavan Disease - Companies Involved in Therapeutics Development
  • Turing Pharmaceuticals AG

For more information about this report visit http://www.researchandmarkets.com/research/5b2rs2/canavan_disease


© Business Wire 2016
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
04:38p Global Canavan Disease Pipeline Review, H2 2016 Featuring Turing Pharmaceuticals AG - Research and Markets
04:38p Polygon Wins Manager of the Year and Convertible Fund of the Year
04:38p J.M. HUBER CORPORATION : Reaches Agreement to Sell Silica Business to Evonik for $630 Million
04:36p Russia to hold additional talks before OPEC, non-OPEC meeting - sources
04:35p AMERICAN AIRLINES : raises fourth-quarter unit revenue forecast
04:35p DOURADO RESOURCES : Cleansing Prospectus - 9 December 2016
04:35p CBS STATISTICS NETHERLANDS : EU countries buying more clothing from Asia
04:35p UPSNAP : Announces third quarter 2016 financial results
04:35p EUROPEAN COMMISSION DIRECTORATE GENERAL FOR INTE : Job opportunities with International Cooperation and Development
04:35p PRESIDENT OF UNITED STATES : Statement by NSC Spokesperson Ned Price on National Security Advisor Susan E. Rice’s Meeting with State Councilor Guo Shengkun of China
Latest news
Advertisement
Hot News 
-15.71%RESTORATION HARDWARE : Hit by Business-Model Changes
6.14%GEMALTO : 3M to sell identity management business to Gemalto
1.99%BANK OF CHINA : Leads Bailout of Troubled Steel Trader
4.78%France's Elior eyes further profit, sales growth
4.87%ASTRAZENECA : FDA Accepts License Application for Durvalumab
Most Read News
08:17a REDROW : Trade gap narrows in October, construction lacklustre
05:48a Macau eases gambling crackdown concerns after casino shares tumble
04:25aDJStocks Continue On Track For Weekly Gains
12/08 U.S. SEC enforcement chief Ceresney to depart at year-end
10:13a TSX eyes 1.8 percent gain on week as banks, energy shares rise
Most recommended articles
12/02 Platts considers first addition to Brent basket since 2007
10:35a AMERICAN AIRLINES : raises fourth-quarter unit revenue forecast
10:31a SEARS CANADA : posts bigger quarterly loss
10:31aDJASTRAZENECA : FDA Accepts License Application for Durvalumab
10:21aDJTransocean Files 8K - Asset Acquisition Or Disposition